Leishmaniasis vaccine trial to start in Sudan
This article was originally published in Scrip
Executive Summary
A Phase I trial has started in Sudan to test a therapeutic vaccine against post kala-azar dermal leishmaniasis (PKDL), a complication of the visceral form of the parasitic disease. Leishmaniasis is found in parts of the tropics, subtropics and southern Europe, with Sudan having the highest number of PKDL cases in the world.